• Jefferies upgraded Praxis Precision Medicines (NASDAQ:PRAX) to a "Buy" rating, increasing the price target from $300 to $450.
• PRAX's stock has experienced a 520% increase over the past three months, driven by promising results from its Essential3 program for treating essential tremor.
• The company's market capitalization stands at approximately $5.58 billion, with a recent slight decrease in stock price to $264.06.

Praxis Precision Medicines, listed on the NASDAQ as PRAX, is a biopharmaceutical company focused on developing treatments for central nervous system disorders. On December 9, 2025, Jefferies upgraded PRAX's stock to a "Buy" rating, with a price target increase from $300 to $450. At the time, the stock was priced at $264.63.

PRAX's stock has seen a remarkable 520% increase over the past three months. This surge is largely due to promising results from late-stage studies of ulixacaltamide, their lead candidate for treating essential tremor. The Essential3 program showed strong efficacy, meeting all primary endpoints and most key secondary measures.

The stock is currently priced at $264.06, reflecting a slight decrease of 2.55% or $6.92. Today, it fluctuated between $263.01 and $276.82. Over the past year, PRAX has seen a high of $278.44 and a low of $26.70, indicating significant volatility.

Praxis's market capitalization is approximately $5.58 billion, with a trading volume of 238,597 shares. The company's progress on pre-New Drug Application steps and positive data for relutrigine have further fueled the stock's recent rally, with a regulatory filing expected in early 2026.